These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The utility of prostate-specific antigen in the management of advanced prostate cancer. Crawford ED; Bennett CL; Andriole GL; Garnick MB; Petrylak DP BJU Int; 2013 Sep; 112(5):548-60. PubMed ID: 23826876 [TBL] [Abstract][Full Text] [Related]
5. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR; Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313 [TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Grossmann M; Zajac JD Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052 [TBL] [Abstract][Full Text] [Related]
7. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142 [TBL] [Abstract][Full Text] [Related]
8. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Taylor LG; Canfield SE; Du XL Cancer; 2009 Jun; 115(11):2388-99. PubMed ID: 19399748 [TBL] [Abstract][Full Text] [Related]
9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258 [TBL] [Abstract][Full Text] [Related]
10. The role of androgen deprivation therapy plus radiation therapy in patients with non-metastatic prostate cancer. Zhao S; Urdaneta AI; Anscher MS Expert Rev Anticancer Ther; 2016 Sep; 16(9):929-42. PubMed ID: 27464256 [TBL] [Abstract][Full Text] [Related]
11. Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. Isbarn H; Boccon-Gibod L; Carroll PR; Montorsi F; Schulman C; Smith MR; Sternberg CN; Studer UE Eur Urol; 2009 Jan; 55(1):62-75. PubMed ID: 18945543 [TBL] [Abstract][Full Text] [Related]
17. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement. Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914 [TBL] [Abstract][Full Text] [Related]
18. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616 [TBL] [Abstract][Full Text] [Related]
19. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Roach M Cancer; 2014 Jun; 120(11):1620-9. PubMed ID: 24591080 [TBL] [Abstract][Full Text] [Related]
20. Management of complications of androgen deprivation therapy in the older man. Mohile SG; Mustian K; Bylow K; Hall W; Dale W Crit Rev Oncol Hematol; 2009 Jun; 70(3):235-55. PubMed ID: 18952456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]